Evidence map›Paper›PMID 30721448›Full record

ArticleMolecular neurobiology2019

Wide Profiling of Circulating MicroRNAs in Spinocerebellar Ataxia Type 7.

Verónica M Borgonio-Cuadra, Claudia Valdez-Vargas, Sandra Romero-Córdoba, Alfredo Hidalgo-Miranda, Yessica Tapia-Guerrero, César M Cerecedo-Zapata, Oscar Hernández-Hernández, Bulmaro Cisneros, Jonathan J Magaña

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Biomarkers in Spinocerebellar Ataxias.Cerebellum (London, England) · 2025
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Spinocerebellar ataxia clinical trials: opportunities and challenges.Annals of clinical and translational neurology · 2021
    Review
  10. Review
  11. Review
  12. Molecular Targets and Therapeutic Strategies in Spinocerebellar Ataxia Type 7.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019
    Review
  13. The Emerging Role of microRNAs in Polyglutamine Diseases.Frontiers in molecular neuroscience · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Verónica M Borgonio-CuadraLaboratory of Genomic Medicine, Department of Genetics, National Rehabilitation Institute (INR-LGII), Calz. México-Xochimilco No. 289, Col. Arenal Guadalupe, 14389, Ciudad de México (CDMX), Mexico.
Claudia Valdez-VargasLaboratory of Genomic Medicine, Department of Genetics, National Rehabilitation Institute (INR-LGII), Calz. México-Xochimilco No. 289, Col. Arenal Guadalupe, 14389, Ciudad de México (CDMX), Mexico.
Sandra Romero-CórdobaLaboratory of Cancer Genomics, National Genomics Medicine Institute (INMEGEN), Mexico City, Mexico.
Alfredo Hidalgo-MirandaLaboratory of Cancer Genomics, National Genomics Medicine Institute (INMEGEN), Mexico City, Mexico.
Yessica Tapia-GuerreroLaboratory of Genomic Medicine, Department of Genetics, National Rehabilitation Institute (INR-LGII), Calz. México-Xochimilco No. 289, Col. Arenal Guadalupe, 14389, Ciudad de México (CDMX), Mexico.
César M Cerecedo-ZapataRehabilitation and Special Education Center of Veracruz (CRIS-DIF), Xalapa, Veracruz, Mexico.
Oscar Hernández-HernándezLaboratory of Genomic Medicine, Department of Genetics, National Rehabilitation Institute (INR-LGII), Calz. México-Xochimilco No. 289, Col. Arenal Guadalupe, 14389, Ciudad de México (CDMX), Mexico.
Bulmaro CisnerosDepartment of Genetics and Molecular Biology, Center of Research and Advanced Studies (CINVESTAV-IPN), Av. Instituto Politécnico Nacional No. 2508, Col. San Pedro Zacatenco, 07360, Ciudad de México (CDMX), Mexico. bcisnero@cinvestav.mx.
Jonathan J MagañaLaboratory of Genomic Medicine, Department of Genetics, National Rehabilitation Institute (INR-LGII), Calz. México-Xochimilco No. 289, Col. Arenal Guadalupe, 14389, Ciudad de México (CDMX), Mexico. maganasm@hotmail.com.ORCID http://orcid.org/0000-0003-4399-4618
National Institute of Genomic Medicine · MXCentro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional · MXEl Colegio de Veracruz · MX

Funding

CONACyT CB-2015-01-258043
6 · The paper itself

Abstract

Spinocerebellar ataxia type 7 (SCA7), a neurodegenerative disease characterized by cerebellar ataxia and retinal degeneration, is caused by a CAG repeat expansion in the ATXN7 gene coding region. Disease onset and progression are highly variable between patients, thus identification of specific/sensitive biomarkers that can improve the monitoring of disease progression is an immediate need. Because altered expression of circulating microRNAs (miRNAs) has been shown in various neurological diseases, they could be useful biomarkers for SCA7. In this study, we showed, to our knowledge for the first time, the expression profile of circulating miRNAs in SCA7. Using the TaqMan profiling low density array (TLDA), we found 71 differentially expressed miRNAs in the plasma of SCA7 patients, compared with healthy controls. The reliability of TLDA data was validated independently by quantitative real-time polymerase chain reaction in an independent cohort of patients and controls. We identified four validated miRNAs that possesses the diagnostic value to discriminate between healthy controls and patients (hsa-let-7a-5p, hsa-let7e-5p, hsa-miR-18a-5p, and hsa-miR-30b-5p). The target genes of these four miRNAs were significantly enriched in cellular processes that are relevant to central nervous system function, including Fas-mediated cell-death, heparansulfate biosynthesis, and soluble-N-ethylmaleimide-sensitive factor activating protein receptor pathways. Finally, we identify a signature of four miRNAs associated with disease severity that discriminate between early onset and adult onset, highlighting their potential utility to surveillance disease progression. In summary, circulating miRNAs might provide accessible biomarkers for disease stage and progression and help to identify novel cellular processes involved in SCA7.

Indexed as

Gene Expression ProfilingAdultCirculating MicroRNAFemaleHumansMaleMiddle AgedSpinocerebellar AtaxiasCirculating MicroRNAmiRNAsPlasma biomarkerPolyQ diseaseSpinocerebellar ataxia type 7

Identifiers

PMID30721448
OpenAlexW2914992142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.